# Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

> **NCT05413551** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 73 (actual)

## Conditions studied

- Tuberculosis Infection
- Isoniazid Adverse Reaction

## Interventions

- **DRUG:** Low-dose isoniazid
- **DRUG:** Standard dose of isoniazid
- **DRUG:** High-dose isoniazid

## Key facts

- **NCT ID:** NCT05413551
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-23
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-06-25
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05413551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05413551, "Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05413551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*